Posts Tagged 'AstraZeneca'

Trouble for Diabetes Drug Makers?

invokana and farxiga mdls to move forwardKnown as SGLT2 inhibitors for short, sodium glucose co-transporter 2 inhibitors are a class of drugs intended for certain individuals with Type II diabetes. The drugs prevent glucose from being absorbed in the kidneys and reduce glucose in the blood by causing it to be expelled in the urine.

Unfortunately, this relatively new class of drugs has already allegedly caused enough harm to warrant FDA action ...

continue reading...

Good News for AZ’s Brilinta; Other Blood Thinners Still Struggle

Pharmaceutical giant AstraZeneca has been given the go-ahead to market a new, 60-milligram dose of their blood thinner Brilinta for longer-term use in patients who have suffered heart attacks. According to Reuters, the U.S. Food and Drug Administration (FDA) approved the new dose for use along with aspirin at any time after a heart attack. Brilinta, an antiplatelet drug used to prevent blood clots, was previously available only at a higher dosage, and could ...

continue reading...

FDA Panel Recommends Heart Warning for Onglyza

FDA suggests heart warning for onglyzaThe FDA is recommending that the pharmaceutical giant AstraZeneca include information about increased risk of heart failure on the label of its diabetes drug Onglyza.

An FDA advisory panel met on April 14 to discuss data linking AstraZeneca’s Onglyza, as well as Takeda’s diabetes drug, Nesina, to increased risk of hospitalization due to heart failure. According to Bloomberg, 14 of 15 panel members voted in favor of recommending that AstraZeneca add ...

continue reading...

FDA: AstraZeneca’s Diabetes Drug Onglyza May Pose Increased Risk of Death

onglyza may cause risk of heart failureA new FDA report has concluded that AstraZeneca’s new diabetes drug Onglyza may be associated with an increased risk of death, Reuters reports.

This is not the first time AstraZeneca has come under scrutiny for its anti-diabetic drugs. As early as 2008, the FDA began receiving reports of hemorrhagic and necrotizing pancreatitis developing in patients taking AstraZeneca’s incretin mimetic drug Byetta, used to treat type 2 diabetes. ...

continue reading...

New AstraZeneca Study Shows Mixed Results for Blood-Thinning Drug

The results of AstraZeneca’s recent trials for its blood-thinning drug Brilinta show a decreased risk of post–heart attack heart problems but an increased risk of major bleeding after using the drug. The pharmaceutical company’s large-scale PEGASUS-TIMI 54 trial included 21,000 patients who had suffered at least one heart attack in the past three years. Patients received either a high dose of Brilinta, a low dose of Brilinta, or a placebo drug. All patients additionally received aspirin ...

continue reading...

FDA Drug Approvals Hit 18 Year High

In 2014, the FDA Center for Drug Evaluation and Research approved the most drugs since 1996. The FDA approved 41 novel medications last year, 62% more than the 27 approved in 2013. The only year that topped 2014 was 1996, when 53 new drugs were approved.

The new drug approvals consisted mostly of innovative, expensive treatments where competition is limited and costs of treatment can often exceed $100,000 per patient per year. Infectious disease drugs received ...

continue reading...
Page 1 of 2 12